News

Approximately 94% of patients treated with 0.3mg of Lucentis and 96% of those treated with 0.5mg of the drug maintained or improved vision, compared to approximately 64% of

The twelve-month, placebo-controlled study is designed to evaluate the ability of OT-551 to prevent or arrest the progression of cataracts in patients who have undergone vitrectomy surgery, a

Guidant believes that Johnson & Johnson is legally bound to complete the acquisition under their agreement signed in December 2004. However, J&J will argue that recent product recalls

Designation as a fast track drug product provides for expedited regulatory review for new drugs demonstrating the potential to address unmet medical needs for the treatment of serious

It is estimated that nearly two million Americans suffer from moderate to severe psoriasis, a chronic, immune-mediated inflammatory disease that can be both physically and emotionally debilitating. The

Data from the study showed PBT2 was well tolerated with little difference in the incidence of adverse events between those receiving PBT2 and those receiving the placebo. In

The study is part of a broad phase II development program of ISIS 301012, a second-generation antisense drug. ISIS 301012 selectively reduces apoB-100, a target critical to the

The first such product that Cobra will develop will be Lovaxin C, Advaxis’ therapeutic vaccine for the treatment of cervical and head and neck cancers that will be

The study will evaluate the safety and efficacy of Davanat with 5-Fluorouracil (5-FU) in combination with irinotecan or oxaliplatin for second line treatment of patients with metastatic colorectal